NEXSEN LIMITED — Capital/Financing Update 2026

Jan 22, 2026

ASX Release | 23 January 2026

==> picture [109 x 61] intentionally omitted <==

==> picture [256 x 18] intentionally omitted <==

Nexsen Limited (ASX:NXN) (“Nexsen” or the “Company”) provides the following notice under ASX Listing Rule 3.10A in relation to the upcoming release of securities from escrow.

The following Fully Paid Ordinary Shares (“Shares”) are due to be released in the next month:

Number and Class	ASX Code	Release Date
6,000,000 Shares	NXNAA	5 February2026
14,200,000 Shares	NXNAB	24 February2026

NXNAA is held by RMIT University, the key research partner to Nexsen across its suite of rapid point-of-care diagnostics development. NXNAB is held by various pre-IPO investors in the Company.

These Shares are presently unquoted (as they are ASX restricted securities). The Company will seek quotation of these Shares following their release from escrow. These Shares are on the same terms and rank equally with all other Shares on issue.

==> picture [25 x 8] intentionally omitted <==

ASX release authorised by the Managing Director.

==> picture [187 x 11] intentionally omitted <==

Corporate Enquiries

Nexsen Limited Reign Advisory

e: corporate@nexsen.bio e: NXN@reignadvisory.com w: nexsen.bio p: + 61 2 9174 5388

Media Enquiries

Jane Morgan Management e: info@janemorganmanagement.com.au

==> picture [141 x 12] intentionally omitted <==

==> picture [26 x 12] intentionally omitted <==

Join our Investor Centre

==> picture [48 x 8] intentionally omitted <==

----- Start of picture text -----

SCAN ME
----- End of picture text -----

==> picture [102 x 101] intentionally omitted <==

Nexsen is developing a suite of rapid point-of-care diagnostics that deliver lab-grade results for conditions that have traditionally relied on delayed lab testing. The company focuses on areas of significant unmet clinical need, where faster answers can improve patient outcomes and reduce pressure on healthcare systems.

Nexsen’s lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The company is also developing rapid kidney function tests for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.

With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.

==> picture [596 x 54] intentionally omitted <==

----- Start of picture text -----

Nexsen Limited nexsen.bio
ASX:NXN ACN 655 182 497
----- End of picture text -----